Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium.
about
Infliximab-Related Infusion Reactions: Systematic ReviewInfliximab in the treatment of plaque type psoriasis.Infliximab therapy in pediatric Crohn's disease: a review.Combination therapy for the treatment of Crohn's disease.Managing complicated Crohn's disease in children and adolescents.Toxicity of infliximab in the course of treatment of Crohn's disease.Update in the treatment of paediatric ulcerative colitis.Infliximab therapy for pediatric Crohn's disease.Review and clinical perspectives for the use of infliximab in ulcerative colitis.Short-term response to adalimumab in childhood inflammatory bowel disease.Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.Specific considerations in the treatment of pediatric inflammatory bowel disease.Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel diseaseA decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.Antitumor necrosis factor treatment for pediatric inflammatory bowel disease.Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?Pediatric ulcerative colitis: current treatment approaches including role of infliximab.Infliximab for the treatment of pediatric ulcerative colitis.Immune-mediated reactions to anti-tumor necrosis factors in inflammatory bowel disease.Premedication Use Before Infliximab Administration: A Cross-sectional Analysis.Biologics in dermatology: adverse effects.Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study.Prevention of acute adverse events related to infliximab infusions in pediatric patients.Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort.Rapid Infliximab Infusion in Children with Inflammatory Bowel Disease: A Multicenter North American Experience.Meta-analysis: rapid infliximab infusions are safe.Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease.Frequency of Severe Infusion Reactions Associated With Outpatient Infusion of Infliximab Without Premedications.“New drugs: Kids come first”: Children should be included in trials of new biological treatments
P2860
Q27013835-8ED20233-ED11-47EE-8D55-934D9D06777DQ34620291-D53D8B47-AE49-41F6-9432-EFEB7A419ED8Q35026358-4B2ABBBA-AC11-44F9-829E-5763D899D949Q35714202-B04EFF46-3497-4E68-8F8E-17910E947F2BQ36331225-5F553199-5C4C-4DF3-9409-632683131967Q36349717-3712729C-02DE-4AD8-9402-BE60A9528272Q36613876-762AB6BF-4BF7-467F-9541-EEA6599AB4E3Q37012073-5B6A60BA-71F8-4B67-9F94-BDFF1A847632Q37114650-D3FE6182-751A-4AB3-BA9D-6FB2822DF470Q37212946-67F97DC4-8274-4651-9606-3242BFFA60B4Q37223169-FB8AA512-332D-429F-BD1B-E4E8FBDDE244Q37345918-071267CF-E94B-4BE5-98BE-18CDDDCA04FFQ37609746-C216C9F1-D1C8-4142-85ED-E0277005E4CDQ37814549-09E4ECEE-0A1A-4B6B-9B1A-6861A6A48CD6Q37820898-7A7DC6B1-02BD-4897-B3C3-0868F1F086F4Q37936394-0284DC3B-4E64-4DA4-AB5F-A14B83490CA7Q37965581-62D6ACC5-D54A-4A4E-B403-9B83AA48F23FQ38022238-0FBE1F2E-5F36-4A7B-84E6-33438F135C2FQ38067127-EFC2FEAD-7135-4404-80B6-42FF8C82C769Q38315640-50D23686-C144-47BD-BC6E-86D79515230DQ39046634-820E914F-FBEF-4208-881D-DEDC61F711ABQ41120913-08EC93EC-6F69-4AC4-A0A1-62D9DC48949DQ42551648-E637E28F-C144-4B00-A15E-BA1C74E4C230Q43035857-183978C2-B059-45E2-B6C2-0407C48963DAQ43633425-E514065D-06DB-4A1B-9853-143221E92148Q46127802-74231CF8-B9F5-47CA-8302-26C1BB3F2046Q48215570-F7EF71A5-8853-49C5-A8BF-34BB48A43475Q48250204-8626FC1C-A276-479E-B8C0-CE575BB4B5DFQ49927683-79F214E9-8084-4C77-88AD-A27DBB95B898Q57804309-9EA81B89-3854-4234-A2C0-0777D446EE82
P2860
Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Premedication and infusion rea ...... tory bowel disease consortium.
@en
Premedication and infusion rea ...... tory bowel disease consortium.
@nl
type
label
Premedication and infusion rea ...... tory bowel disease consortium.
@en
Premedication and infusion rea ...... tory bowel disease consortium.
@nl
prefLabel
Premedication and infusion rea ...... tory bowel disease consortium.
@en
Premedication and infusion rea ...... tory bowel disease consortium.
@nl
P2093
P2860
P1476
Premedication and infusion rea ...... tory bowel disease consortium.
@en
P2093
Benjamin D Gold
Douglas A Jacobstein
George Ferry
Harland S Winter
Jonathan E Markowitz
Melvin B Heyman
Robert N Baldassano
Stanley A Cohen
P2860
P304
P356
10.1097/01.MIB.0000158166.88238.EA
P577
2005-05-01T00:00:00Z